The time to build it is now!’
What this patent means This specific health technology is • recognized by a government agency, • novel and has not existed before, • unique and not available anywhere else, • protected and cannot be imitated.
What is the difference from a pharmaceutical drug patent
Target markets
Purpose of patents This information sheet provides health research established in con nection with natural disease pre vention. For patients, we rec ommend to see a therapist or trained consultant to determine your individual health needs.
www.drrathresearch.org
Consequences for your health Consequences for national economies
#1896/01EN/231122 Art. Nr.: 30005
The Dr. Rath organization oper ates under a nonprofit roof and all profits are used to promote further independent research and education in natural health.
E US PAT TH
P
Over the ensuing decades, the Institute’s research team, under the leadership of Dr. Aleksandra Niedzwiecki, has extended this life saving research to comprise natu ral prevention of cancer, diabetes, viral and bacterial infections and Senior scientists of the Dr. Rath many other diseases. Research Institute with The approval of this preventive Dr. Niedzwiecki (center) health research by patent offices Dr. Rath Research Institute around the world provides the sci in San Jose, California entific basis for effective preven tive health strategies globally. Pa tients, therapists, governments and, above all, millions of people now have effective, safe, natural health approaches avilable to help to prevent widespread diseases.
Patented technology to help to optimize blood pressure ENT OF AT
Dr. Matthias Rath
Micronutrients and Blood Pressure
Pharmaceutical investment business
Natural health community
Disease management
Disease prevention
Legal tools to secure return on investment (ROI) Cementing continua tion of diseases as global markets
Disease prevention and potential elimination
Exploding health care costs
Less diseases = lower health care costs
Scientific acknowledgement
Natural health research – the basis of preventive health
High blood pressure
T OFFIC EN
The Dr. Rath Research Institute is a world leader in sciencebased natural health. Three decades ago, Dr. Matthias Rath – together with twotime Nobel Laureate Dr. Linus Pauling (†1994) – was already pub lishing groundbreaking discoveries on the importance of vitamins in fighting cardiovascular diseases.
‘Science‐based natural health is the basis of modern, preventive health care.
E
Nobel Prize‐winner‐supported research paves the way to preventive health care
Micronutrient combinations can help improve key mechanisms of high blood pressure
The world’s first patented technology to help to normalize high blood pressure – naturally
The following graphs are taken from this patent. They show:
1. Micronutrient combination increases the production of ‘relaxing factor’ (NO) in human aortic muscle cells
Conventional medicine concedes that in most patients the cause of high blood pressure is unknown. A special ‘diagnosis’ is even being used to mask that fact. For millions of patients the term ‘essential hy pertension’ suggests a precise dia gnosis — in reality it is the code within the medical profession for ‘we don’t know.’ Thus, conventional pharmaceuti caloriented medicine is essen tially limited to treating the symptoms of this disease. So
US Patent Publ. No. US20220241386A1
Micronutrient combination to reduce high blood pressure Inventors: Aleksandra Niedzwiecki, Matthias Rath, Vadim Ivanov, Waldemar Sumera Publishing date: August 4, 2022
These drugs address symptoms without correcting the root cause of the problem. Modern scientific understanding provides logical answers: the pri mary cause of hypertension is a deficiency of vitamins and micro nutrients in the small muscle cells (smooth muscle cells) building up
• Increasing relaxing factors Among other functions, these cells are responsible for producing ‘re laxing factors‘ (nitric oxide), which decrease vascular wall tension and keep the blood pressure in normal range. Thus, increasing the pro duction of these relaxing factors is an important target for preventing high blood pressure. • Decreasing constriction factors Another key regulator of artery wall tension is angiotensin. The ac tive hormone angiotensin II con tributes to the regulation of our body fluids. Its overproduction leads to a constriction of the ar tery walls and to elevated blood pressure. Angiotensin I (inactive hormone)
Angiotensin II (active hormone)
Angiotensinconverting enzyme (ACE)
Wide artery diameter: Normal blood pressure
called ACE (angiotensinconverting enzyme) inhibitors, betablockers, diuretics and other high blood pressure medications can artifi cially lower the blood pressure.
Narrow artery diameter: Elevated blood pressure Find further information and studies on high blood pressure on this website.
The angiotensinconverting enzyme (ACE) converts the inactive angio tensin I hormone into the active hormone that constricts the blood vessel wall and increases blood pressure. Lowering the activity of ACE is therefore desirable to nor malize high blood pressure.
The Dr. Rath Research Institute in vestigated a composition of vita mins and other micronutrients for their efficacy to affect both of these mechanisms.
Vitamin C B vitamins Vitamin D3 Folate Calcium Magnesium Larginine and other micronutrients
Based on the research results ob tained with this micronutrient composition, the Patent Office al lowed the following statements to be made in connection with high blood pressure conditions:
Excerpts of patent claims: • ‘A high blood pressure redu cing micronutrient composi tion.’ • This micronutrient composi tion can be administered ‘to relax a smooth muscle cell for lowering high blood pres sure.’
250
200
Control 150
100
50
0
0
2.5
5
Micronutrient composi�on concentra�on, mcg/ml
1. The micronutrient combination has the ability to increase the pro duction of relaxing factors (NO) in the smooth muscle cells of human arteries in a dosedependent manner. At higher concentrations, the NO production is more than doubled compared to controls.
2. Micronutrient combination decreases the angiotensinconverting enzyme (ACE) activity 120
Cell protec�on in % ACE ac�vity, % of control
About 100 million people in Europe suffer from high blood pressure conditions, also known as hypertension. The epidemic spread of this disease owes much to the fact that, until now, the causes of high blood pressure have not been fully understood.
the artery walls regulating the ten sion of the blood vessel wall and, thereby, the blood pressure.
Cell protec�on in % Nitrites, % of control
300
Facts about high blood pressure
Control 100
80
60
40
20
0
0
3
13
50
200
Micronutrient composi�on concentra�on, mcg/ml
2. The micronutrient combination has the ability to decrease the ac tivity of ACE, thereby functioning as a natural ACE inhibitor, contrib uting to the decrease of elevated blood pressure.